|Bid||31.59 x 900|
|Ask||31.64 x 1000|
|Day's Range||30.45 - 31.86|
|52 Week Range||17.88 - 45.02|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 5, 2018 - Nov 9, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||45.20|
Get ready for a golden age of medicine that could dramatically shake up which biotechs get the gold.
The Oracle of Omaha hasn't invested in these areas. But they're great opportunities for investors who aren't already billionaires.
Editas Medicine, Inc. (EDIT), a leading genome editing company, announced today the National Institutes of Health (NIH) Recombinant DNA Advisory Committee (RAC) completed the NIH protocol registration process for EDIT-101. The NIH determined a public meeting is not necessary, and the RAC will not be convened to review this clinical trial. EDIT-101 is Editas Medicine’s experimental CRISPR genome editing medicine for the treatment of Leber Congenital Amaurosis type 10 (LCA10).
The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers
Novo Nordisk (NVO) reports strong Q2 results. J&J (JNJ) seeks approval for new dosing regimen of multiple myeloma drug. Allergan (AGN) exercises option to buy Editas' lead ocular candidate.
Investors need to pay close attention to Editas Medicine (EDIT) stock based on the movements in the options market lately.
In May 2018, Editas Medicine (EDIT) and Juno Therapeutics amended and restated their 2015 collaboration and license agreement. This collaboration is focused on researching and developing engineered T cells with chimeric antigen receptors (or CARs) and T cell receptors (or TCRs) that are genetically modified to kill other cells. Editas Medicine entered a strategic alliance and option agreement with Allergan Pharmaceuticals in March 2017 for discovering, developing, and commercializing new gene editing products targeted at ocular diseases.
Editas Medicine (EDIT) generated collaboration and research and development revenues of $7.37 million in the second quarter of 2018 compared with $3.1 million in the second quarter of 2017. This increase was attributable to the $3.9 million the company received under a license agreement with Beam Therapeutics and $2.8 million higher revenues recognized under a collaboration agreement with Juno Therapeutics.
Editas Medicine (EDIT) is a research-stage genome editing company. Editas makes use of clustered, regularly interspaced, short palindromic repeats (or CRISPR) technology and has developed a proprietary genome editing platform based on it with a product development strategy to chiefly target genetically defined diseases.
The genome-editing specialist just offered its latest update on the state of the business. Here's what investors need to know.
NEW YORK, NY / ACCESSWIRE / August 7, 2018 / U.S. markets closed in the green on Monday, as Nasdaq surged for the fifth consecutive session, on a batch of strong corporate earnings, amidst ongoing trade-related ...
Editas (EDIT) delivered earnings and revenue surprises of -18.84% and 18.90%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 82 cents. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks ...
Allergan exercises option to develop and commercialize EDIT-101 globally and Editas exercises option to co-develop and equally share profits and losses in the United States. Plan to file EDIT-101 Investigational ...
DUBLIN and CAMBRIDGE, Mass., Aug. 6, 2018 /PRNewswire/ -- Allergan plc (AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced that Allergan's wholly-owned subsidiary, Allergan Pharmaceuticals International Limited (Allergan), has exercised its option to develop and commercialize EDIT-101 globally for the treatment of LCA10. Additionally, the two companies announced that Editas Medicine has exercised its option to co-develop and share equally in the profits and losses from EDIT-101 in the United States.
Allergan plc (AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced that Allergan’s wholly-owned subsidiary, Allergan Pharmaceuticals International Limited (Allergan), has exercised its option to develop and commercialize EDIT-101 globally for the treatment of LCA10. Additionally, the two companies announced that Editas Medicine has exercised its option to co-develop and share equally in the profits and losses from EDIT-101 in the United States.
NEW YORK, NY / ACCESSWIRE / August 6, 2018 / Editas Medicine, Inc. (NASDAQ: EDIT ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 6, 2018 at 5:00 PM Eastern Time. ...
Not every Fool fan can make it to Alexandria, Virginia, for our big member shindig, so we’re bringing you one of the highlights.
Editas Medicine (EDIT) is expected to report its second-quarter earnings results on August 8. In this series, we’ll take a look at analysts’ expectations for the company’s top line, operational performance, and bottom line performance in the quarter along with their recommendations for its stock. Editas Medicine is a clinical-stage genome editing company.
Editas Medicine’s (EDIT) general and administrative expenses are expected to rise 39.57% YoY (year-over-year) from $11.89 million to $16.60 million in the second quarter, and its research and development expenses are expected to increase 39.16% YoY from $17.32 million to $24.10 million in the second quarter. Editas Medicine is expected to have a net income of -$32.88 million in the second quarter compared to its net income of -$26.44 million in the second quarter of 2017. This net income translates to a net income per share of -$0.67 in the second quarter of 2018 compared to a net income per share of -$0.65 in the second quarter of 2017.
The stock prices of gene-editing companies like CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), and Intellia Therapeutics (NTLA) saw a sharp correction in July. These companies are focused on clustered, regularly interspaced, short palindromic repeats (or CRISPR) technology, and have fallen on concerns stemming from a recently published study.
CAMBRIDGE, Mass., July 30, 2018-- Editas Medicine, Inc., a leading genome editing company, today announced that it will host a conference call and webcast on Monday, August 6, 2018, at 5:00 p.m. ET to ...